Advice

in the absence of a submission from the holder of the marketing authorisation:

brentuximab vedotin (Adcetris®) is not recommended for use within NHSScotland.

Indication under review: treatment of adult patients with CD30+ cutaneous T-cell lymphoma after at least one prior systemic therapy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download full details214KB (PDF)

Download

Medicine details

Medicine name:
brentuximab vedotin (Adcetris)
SMC ID:
SMC2098
Indication:
treatment of adult patients with CD30+ cutaneous T-cell lymphoma after at least one prior systemic therapy.
Pharmaceutical company
Takeda UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
09 July 2018